Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0050922 |
| Name | gastrointestinal carcinoma |
| Definition | A gastrointestinal system cancer that has_material_basis_in epithelial cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastrointestinal carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03724071 | Phase Ib/II | Flucytosine + TG6002 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | Terminated | FRA | ESP | BEL | 0 |
| NCT04426669 | Phase Ib/II | Aldesleukin + CISH-inactivated autologous TILs + Cyclophosphamide + Fludarabine | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | Active, not recruiting | USA | 0 |
| NCT05848843 | Phase I | Adagrasib + Durvalumab | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | USA | 0 |
| NCT06690281 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin + Autologous KRAS mutant TCR-transduced PBLs | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | Withdrawn | USA | 0 |